Actavis shareholders approve Warner Chilcott acquisition proposals

By

Back to Top Comments Email Print

Parsippany-based specialty pharmaceutical company Actavis announced today its shareholders have approved several proposals related to the company's acquisition of Warner Chilcott. The approvals were required under closing conditions for the acquisition, which is expected to close early in the fourth quarter.

The acquisition, first announced in May, consists of a $5 billion stock swap of 0.16 of an Actavis share for each Chilcott share, valuing the Chilcott shares at $20.08 each. Current Actavis leadership will oversee the resulting company, Actavis PLC.

 

 

 

 

 

Share This Story On:

Write to the Editorial Department at editorial@njbiz.com

advertisement

Comments


Be the first to comment.


You must log in before you can post comments.

Back to Top